Compare Johnson & Johnson (JNJ) vs LyondellBasell Industries NV (LYB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs LyondellBasell Industries NV — how do they compare? Johnson & Johnson trades at $260.22 (market cap $618.09B), while LyondellBasell Industries NV trades at $60.31 (market cap $19.49B). The key difference: Johnson & Johnson is far larger — about 31.7× LyondellBasell Industries NV's market cap, and LyondellBasell Industries NV pays the higher dividend (4.57%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and LyondellBasell Industries NV for 87 Days on average.
| JNJ | LYB | |
|---|---|---|
Market Cap | $618.09B | $19.49B |
Volume | 6,050,983 | 6,033,396 |
Sector | Health | Basic Materials |
52-Week High | $278.43 | $82.38 |
52-Week Low | $186.00 | $42.28 |
Typical Hold Time | 129 Days | 87 Days |
Enterprise Value | $646.37B | $31.08B |
Dividend Yield | 2.09% | 4.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
LYB trades at $60.90, up 4.12% today, with a bearish technical signal and mixed fundamentals. Revenue declined to $30.15B in 2025, with a net loss of $745M, though recent quarters show earnings beats. The stock is near its 52-week low, with key support at $60. Analyst consensus is split evenly between Buy and Hold, with a $69.38 price target. Recent news highlights dividend sustainability concerns amid chemical sector volatility.
Outlook remains cautious due to profitability challenges and high debt, but operational improvements and a 45% analyst buy rating suggest recovery potential. Risks include cyclical demand, margin pressure, and dividend coverage issues. The stock offers value at current levels if earnings stabilize, but investors should monitor cash flow trends and sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →
